Patient Rating:

No Rating Available?

Barbara A. Chatfield, M.D.

Specialties

Languages

  • English

Clinical Details

Schedule An Appointment Clinical Office Address
(801) 213-3599 Primary Children's Hospital
Pediatric Pulmonology
100 N Mario Capecchi Drive
Salt Lake City, UT 84113

Bio

Dr. Chatfield received her medical degree from the Medical College of Virginia at Virginia Commonwealth University. She completed her pediatric residency and pediatric pulmonary fellowship at the University of Colorado Health Sciences Center in Denver, Colorado. Upon completion of fellowship training, she completed a four year active duty tour with the United States Air Force in Biloxi Mississippi where she established the first pediatric pulmonary service in the Air Force. She was also the Director of the Tri-Services CF Center Affiliate at Keesler Medical Center and Director of Pediatric Critical Care Services at Keesler Medical Center. Dr. Chatfield accepted a position at the University of Utah in 1995. Dr. Chatfield was initially the associate director for the Intermountain Cystic Fibrosis Center and was named the Director of this program in 1999.

Dr. Chatfield’s outpatient practice is primarily focused on CF care with CF Clinic being held three days per week. A special block of the clinic is reserved for newborn screen patients. Dr. Chatfield also attends on the general inpatient pulmonary service.

Board Certification and Academic Information

Academic Departments Pediatrics - Professor (Clinical)
Academic Divisions Pediatric Pulmonology

Academic Profile

Research Interests

  • Cystic Fibrosis

Board Certification and Academic Information

Academic Departments Pediatrics - Professor (Clinical)
Academic Divisions Pediatric Pulmonology

Academic Bio

Dr. Chatfield received her medical degree from the Medical College of Virginia at Virginia Commonwealth University. She completed her pediatric residency and pediatric pulmonary fellowship at the University of Colorado Health Sciences Center in Denver, Colorado. Upon completion of fellowship training, she completed a four year active duty tour with the United States Air Force in Biloxi Mississippi where she established the first pediatric pulmonary service in the Air Force. She was also the Director of the Tri-Services CF Affiliate Center at Keesler Medical Center and Director of Pediatric Critical Care Services at Keesler Medical Center. Dr. Chatfield accepted a position as an assistant professor of pediatrics on the clinical track at the University of Utah in 1995. Dr. Chatfield was initially the associate director for the Intermountain Cystic Fibrosis Center and was named the Director of this program in 1999. Dr. Chatfield was promoted to associate professor in 2001 and full professor in 2007.

Dr. Chatfield’s clinical research interests are centered on Quality Improvement in relation to Cystic Fibrosis. The Intermountain Cystic Fibrosis Center participated in the first Learning and Leadership Collaborative sponsored by the Cystic Fibrosis Foundation in 2003. The CF Center has continued to work towards improved outcomes through multiple quality improvement projects. These projects have focused on improvement in nutrition, improved education, infection control and treatment of pulmonary exacerbations. Dr. Chatfield has also worked extensively as a consultant to the Utah Department of Health Newborn Screening Advisory Committee and Genetics Advisory Committee to implement newborn screening for CF in 2009. Dr. Chatfield is a member of the CF Foundation newborn screening quality improvement group.

Dr. Chatfield has also been the Co-PI on the Cystic Fibrosis Foundation Therapeutic Development Center (TDC) Grant since 2006. As a TDC site, the Intermountain Cystic Fibrosis Center has had increased opportunities to participate Phase I and Phase II multi-center clinical trials. The Intermountain CF Center has a track record of excellent enrollment, accurate and careful participation in numerous critical clinical trials. Dr. Chatfield was the site PI for Vertex 08-770-103. This landmark study utilizes VX770 to potentiate the gating of defective CFTR in patients with G551D mutations. This pediatric study has completed enrollment and all study procedures. Based on the findings, Vertex Pharmaceuticals prepared a new drug application to the FDA which was approved in a little over two months from time of submission. This is be the first drug ever approved to target the basic defect causing disease in CF in a select population of CF patients. Dr. Chatfield is also an investigator on trials of Lumacaftor and Ivacaftor which will hopefully target a larger segment of the Cf population-those homozygous for F508del-the most common CF causing mutation. Dr. Chatfield has been the PI on a variety of epidemiologic as well as other drug intervention studies in pediatric patients. These include NIH, Cystic Fibrosis Foundation and industry funded studies.

Dr. Chatfield is the Medical Director for the Cystic Fibrosis Care Center at Primary Children’s Hospital. She works closely with administrators to develop and maintain the multidisciplinary care team and assure CF Foundation standards are being met. In this setting, Dr. Chatfield works with many allied health care providers and mentors them in clinical and educational pursuits. Dr. Chatfield gives regular lectures to nursing, other allied health and house officers on CF related issues. Dr. Chatfield has recently spoken on Newborn Screening at PCH Grand Rounds and traveled with the Health Department to give similar presentations. Dr. Chatfield has been an invited speaker at local, regional and national meetings.

Dr. Chatfield’s outpatient practice is primarily focused on CF care with CF Clinic being held three days per week. A special block of the clinic is reserved for newborn screen patients. Dr. Chatfield also attends on the general inpatient pulmonary service.

Education

Education History

Type School Degree
Fellowship University of Colorado at Denver and Health Sciences Center
Pediatric Pulmonology
Fellow
Residency University of Colorado at Denver and Health Sciences Center
Pediatrics
Resident
Internship University of Colorado at Denver and Health Sciences Center
Pediatrics
Intern
Professional Medical Virginia Commonwealth University
Medicine
M.D.
Undergraduate University of Colorado - Boulder
Molecular, Cellular, and Developmental Biology
B.A.

Publications

Selected Provider Publications

Journal Article

  1. Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW (2012). Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol, 47(2), 125-34.
  2. Zobell JT, Young DC, Waters CD, Ampofo K, Cash J, Marshall BC, Olson J, Chatfield BA (2011). A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients. Pediatr Pulmonol, 46(10), 987-90.
  3. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, Orenstein D, Chatfield BA, Froh DK, Burns JL, Rosenfeld M, Ramsey BW (2011). Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med, 165(9), 847-56.
  4. Zobell JT, Stockmann C, Young DC, Cash J, McDowell BJ, Korgenski K, Sherwin CM, Spigarelli M, Chatfield BA, Ampofo K (2011). Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. Clin Ther, 33(11), 1844-50.
  5. Pohl JF, Judkins J, Meihls S, Lowichik A, Chatfield BA, McDonald CM (2011). Cystic fibrosis and celiac disease: both can occur together. Clin Pediatr (Phila), 50(12), 1153-5.
  6. Pohl JF, Patel R, Zobell JT, Lin E, Korgenski EK, Crowell K, Mackay MW, Richman A, Larsen C, Chatfield BA (2011). Clostridium difficile Infection and Proton Pump Inhibitor Use in Hospitalized Pediatric Cystic Fibrosis Patients. Gastroenterol Res Pract, 2011, 345012.
  7. Borowitz D, Stevens C, Brettman LR, Campion M, Chatfield B, Cipolli M, for the Liprotamase 726 Study Group (08/01/2011). International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients. J Cyst Fibros, 2011(Aug).
  8. Uchida DA, Wert SE, Nogee LM, Carroll TR, Chatfield BA (2011). Pulmonary nodules in a newborn with ATP-binding cassette transporter A3 (ABCA3) mutations. Pediatrics, 2011(May127(5)), 1347-1351.
  9. Zobell JT, Ampofo K, Cash J, Korgenski K, Chatfield BA (2010). High dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. J Cyst Fibros, 9(4), 280-3.
  10. Wooldridge JL, Heubi JE, Amaro-Galvez R, Boas SR, Blake KV, Nasr SZ, Chatfield B, McColley SA, Woo MS, Hardy KA, Kravitz RM, Straforini C, Anelli M, Lee C (2009). EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. J Cyst Fibros, 8(6), 405-17.
  11. Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R, Williams J, Ramsey BW (2007). Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol, 42(7), 610-23.

Letter

  1. Zobell JT, Young DC, Chatfield BA (2013). Intermittent and extended-infusion beta-lactam utilization in cystic fibrosis [Letter to the editor]. Pediatr Pulmonol, 48(6), 622-3.

Abstract

  1. Rosenfeld, M Gison, R Emerson, J McNamara, S Escobar, D Andrina, M Chatfield, BA Orenstein DM, Konstan MW, Rock, M Ramsey, BW (2007). Large US Cohort of Young Pseudomonas Negative CF Patients: Mild Lung Disease, Heterogeneous Mangement [Abstract]. Pediatric Pulmonology, Supplement(30), 332.

Clinical Trials

Video & News